Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma

[1]  Choung-Soo Kim,et al.  Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma. , 2013, Urologic oncology.

[2]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[3]  H. Miyake,et al.  Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. , 2013, Urologic oncology.

[4]  Richard Sylvester,et al.  European guidelines on upper tract urothelial carcinomas: 2013 update. , 2013, European urology.

[5]  E. Kikuchi,et al.  Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. , 2013, The Journal of urology.

[6]  O. Cussenot,et al.  Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study , 2013, World Journal of Urology.

[7]  Y. Miyaji,et al.  Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma , 2012, World Journal of Urology.

[8]  A. Goel,et al.  Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of , 2012, European urology.

[9]  T. O'brien,et al.  Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). , 2011, European urology.

[10]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[11]  C. Kwak,et al.  Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. , 2011, Urologic oncology.

[12]  O. Cussenot,et al.  Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. , 2011, Urologic oncology.

[13]  K. Nakagawa,et al.  Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer. , 2011, The Journal of urology.

[14]  N. Miyanaga,et al.  Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long‐term follow‐up study , 2010, International journal of urology : official journal of the Japanese Urological Association.

[15]  Y. Matsuno,et al.  Pathological characteristics and clinical course of bladder tumour developing after nephroureterectomy , 2010, BJU international.

[16]  P. Tsai,et al.  Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. , 2008, European urology.

[17]  J. Patard,et al.  Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract , 2008, BJU international.

[18]  L. Martínez-Piñeiro,et al.  Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. , 2008, European urology.

[19]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[20]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[21]  M. Jinzaki,et al.  The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. , 2014, Urologic oncology.

[22]  J. Catto,et al.  Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. , 2013, European urology.